Cited by

• External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab.

  Konecki C, Feliu C, Cazaubon Y, Giusti D, Tonye-Libyh M, Brixi H, Cadiot G, Biron A, Djerada Z. Konecki C, et al. Pharmaceutics. 2021 Aug 3;13(8):1191. doi: 10.3390/pharmaceutics13081191. Pharmaceutics. 2021. PMID: 34452152 Free PMC article.
• Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.

  Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G. Ternant D, et al. Br J Clin Pharmacol. 2012 Jan;73(1):55-65. doi: 10.1111/j.1365-2125.2011.04050.x. Br J Clin Pharmacol. 2012. PMID: 21692827 Free PMC article. Clinical Trial.
• Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature.

  Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S. Fobelo Lozano MJ, et al. Br J Clin Pharmacol. 2019 Oct;85(10):2264-2279. doi: 10.1111/bcp.14062. Epub 2019 Aug 6. Br J Clin Pharmacol. 2019. PMID: 31315147 Free PMC article. Review.
• Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.

  Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauféron F, Ternant D, Watier H, Goupille P. Ducourau E, et al. Arthritis Res Ther. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386. Arthritis Res Ther. 2011. PMID: 21708018 Free PMC article.
• Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.

  Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, Perdriger A, Lespessailles E, Martin A, Cormier G, Armingeat T, Devauchelle-Pensec V, Gervais E, Le Goff B, de Vries A, Piver E, Paintaud G, Desvignes C, Ternant D, Watier H, Goupille P, Mulleman D. Ducourau E, et al. RMD Open. 2020 Jan;6(1):e001047. doi: 10.1136/rmdopen-2019-001047. Epub 2020 Jan 9. RMD Open. 2020. PMID: 31958280 Free PMC article. Clinical Trial.